Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Role of metabolic therapy in cardiovascular disease

  • 43 Accesses

  • 11 Citations

Summary

The pathophysiological basis for the use of metabolic therapy in the treatment of heart failure is analyzed. Bioenergetical processes related to ATP bioavailability play a central role in regulating myocardial contractility at rest and on effort. Furthermore, a significant correlation has been demonstrated in diseased heart between ATP content, revealed at endomyocardial biopsy, and systolic and diastolic left ventricular indexes evaluated with invasive and noninvasive methods. Several international investigations demonstrate the beneficial effects of ubiquinone (coenzyme Q10) in the treatment of heart failure. Here the results of a study are reported that was conducted on patients with heart failure treated with ubiquinone. After 7 months of oral drug administration (100 mg/day), a significant improvement was observed in echocardiographic indexes of systolic function, cardiothoracic ratio, and clinical signs and symptoms of congestive heart failure. In conclusion, the introduction of metabolic drugs, such as ubiquinone, in the treatment of heart failure opens new horizons in the therapeutic approach to an ailment that entails substantial human and social costs.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Abete P, Ambrosio G, Santoro G, Lamberti F, Caccese P, Ferrara N, Rengo F, Chiariello M (1990) Giornale di Gerontologia 38:640–641

  2. 2.

    Ambrosio G, Abete P, Santoro G, Lamberti F, Caccese P, Ferrara N, Rengo F, Chiariello M (1990) Age-related decrease in cardiac tolerance to oxidative stress in isolated rat hearts. Circulation 82: III-700

  3. 3.

    Ambrosio G, Flaherty JT, Duilio C, Tritto I, Santoro G, Elia P, Condorelli M, Chiariello M (1991) Oxygen radical generated at reflow induced peroxidation of membrane lipids in reperfused hearts. J Clin Invest 87:2056–2070

  4. 4.

    Anversa P, Olivetti G, Melissari M, Loud AV (1980) Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of adult rat. J Mol Cell Cardiol 12:781–795

  5. 5.

    Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV (1987) Histologic and biomedical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol 9:734–742

  6. 6.

    Beyer RE, Bumett BA, Cartwright KJ, Edington DW, Falzon MJ, Kreitman KR, Kuhn TW, Ramp BJ, Rhee SYS, Rosenwasser MJ, Stein M, Anl C-I (1985) Tissue coenzyme Q (ubiquinone) and protein concentrations over the life span of the laboratory rat. Mech Ageing Dev 32:267–81

  7. 7.

    Blain JM, Shaffer H, Siegel AL, Bing RJ (1956) Studies on myocardial metabolism. VI. Myocardial metabolism in congestive failure. Am J Med 20:820 -833

  8. 8.

    Chatterjee K, De Marco T, Rouleau JL (1988). Vasodilator therapy in chronic congestive heart failure. Am J Cardiol 62:46A–54A

  9. 9.

    Csallany AS (1984). Effect of selenite, vitamin E and N,N′diphenyl-p-phenylenediamine on liver organic solvent soluble lipofuscin pigments in mice. J Nutrition 114:1582–1596

  10. 10.

    Dawson DA, Adams PF (1987). Current estimates from national health interview survey, USA 1988. In: Vital and health statistics. DHHS Publ. N(PHS) Washington, U.S. Government Printing Office, pp 87–1592

  11. 11.

    Folkers K (1984) Perspectives from research on vitamins and hormones. J Chem Educ 61:747–56

  12. 12.

    Folkers K, Vadhanavikit S, Mortensen SA (1985) Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 82:4513–4516

  13. 13.

    Furchgott RF, Lee KS (1961) High energy phosphates and theforce of contraction of cardiac muscle. Circulation 24:416–432

  14. 14.

    Gibson TC, White KL, Klainer LM (1966) The prevalence of congestive heart failure in two communities. J Chronic Dis 19:141–156

  15. 15.

    Harman D (1984) Free radical theory of aging: the “free radical” diseases. Age 7–124

  16. 16.

    Katz AM (1984). Lipofuscin accumulation resulting from senescence and vitamin E deficiency: spectral properties and tissue distribution. Mech Ageing Dev 25:149

  17. 17.

    Katz AM (1989) The myocardium in congestive heart failure. Am J Cardiol 63:12A–16A

  18. 18.

    Klainer LM, Gibson TC, White KL (1965) The epidemiology of cardiac failure. J Clin Dis 18:797–807

  19. 19.

    Kitamura N, Yamaguchi A, Otaki M, Sawatani O, Minoji T, Tamuta H, Atobe M (1984) Myocardial tissue level of coenzyme Q10 in patients with cardiac failure. In: Folkers K, Yamamura Y (eds) Biomedical and clinical aspects of CoQ10, vol 4. Elsevier, Amsterdam pp 243–256

  20. 20.

    Langsjoen PH, Vadhanavikit S, Folkers K (1985) Effective-treatment with coenzyme Q10 of patients with chronic myocardial disease. Drug Exp Clin Res XI: 577–579

  21. 21.

    Langsjoen P, Folkers K, Lyson K, Muratsu K, Lyson T (1986) Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr 66:583–590

  22. 22.

    Langsjoen H, Langsjoen P, Folkers K (1990) Long-term efficacy and safety of coenzyme Q10 therapy for idiopatic dilated cardiomyopathy. Am J Cardiol 65:521–523

  23. 23.

    Littarru GP, Ho L, Folkers K (1972) Deficiency of coenzyme Q10 in human heart disease I. Int J Vitam Nutr Res 42:291–305

  24. 24.

    Littarru GP, Ho L, Folkers K (1972) Deficiency of coenzyme Q10 in human heart disease II. Int J Vitam Nutr Res 42:413–434

  25. 25.

    Mason DT, Zelis R, Wilkman-Coppel T (1973) Symposium on congestive heart failure: recent advances in structure biochemistry, physiology and pharmacology. Am J Cardiol 32:395–410

  26. 26.

    McKee PA, Castel WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. New Engl J Med 285:1441–1457

  27. 27.

    Mortensen SA, Vadnavikit S, Baandrup U, et al. (1985) Long term coenzyme Q10 therapy: a major advance in the management of resistent myocardial failure. Drug Exp Clin Res XI: 581–593

  28. 28.

    Opie LH (1975) Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Am J Cardiol 36:938–945

  29. 29.

    Page E, McCalister LP (1973) Quantitative electron microscopic description of heart muscle cells. Application to normal, hypertrophied and thyroxin-stimulated hearts. Am J Cardiol 31:172–182

  30. 30.

    Pool PE, Spann JF jr, Buccino RA, Sonnenblick EH, Braunwald E (1967) Myocardial high energy phosphates stores in cardiac hypertrophy and heart failure. Circ Res 21:365–373

  31. 31.

    Rabinovitz M (1973). Protein synthesis and turnover in normal and hypertrophied heart. Am J Cardiol 31:202–210

  32. 32.

    Rengo F, Ambrosio G, Abete P, Napoli C, Caccese P, Santoro G, Ferrara N, Chiariello M (1992) Age-related arrhythmogenic effects of oxidative stress in isolated rat heart. The New Frontiers of Arrhythmias 1:941–944

  33. 33.

    Roberts IT, Wearn JT (1941) Quantitative changes in the capillary muscle relation ship in human hearts during normal growth and hypertrophy. Am Heart J 21:617–633

  34. 34.

    Shipley RA, Shipley LJ, Wearn JT (1937). The capillary supply in normal and hypertrophied hearts of rabbits. J Exp Med 65:29–41

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rengo, F., Abete, P., Landino, P. et al. Role of metabolic therapy in cardiovascular disease. Clin Investig 71, S124–S128 (1993). https://doi.org/10.1007/BF00226852

Download citation

Key words

  • Ubiquinone
  • ATP
  • Heart failure